...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Cardiology >Clinical Outcomes After Sirolimus-Eluting, Paclitaxel-Eluting, and Bare Metal Stents (from the First Phase of the Prospective Multicenter German DES.DE Registry)
【24h】

Clinical Outcomes After Sirolimus-Eluting, Paclitaxel-Eluting, and Bare Metal Stents (from the First Phase of the Prospective Multicenter German DES.DE Registry)

机译：西罗莫司洗脱，紫杉醇洗脱和裸金属支架后的临床结果（来自预期的德国多中心DES.DE注册中心的第一阶段）

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The prospective multicenter German Drug-Eluting Stent (DES.DE) registry is an observational study to analyze and evaluate the therapeutic principle of the differential drug-eluting stents (sirolimus- and paclitaxel-eluting stents) and bare metal stents under real world conditions in the context of the German healthcare system. The baseline clinical and angiographic characteristics and follow-up events for 1 year were recorded for all enrolled patients. In addition, a health economics assessment was performed at 3, 6, 9, and 12 months after initial stent placement. The composite of death, myocardial infarction, and stroke, defined as major adverse cardiac and cerebrovascular events, and target vessel revascularization were used as the primary objectives. From October 2005 to October 2006, 6,384 patients were enrolled (sirolimus-eluting stents, n = 2,137; paclitaxel-eluting stents, n = 2,740; bare metal stents, n = 485) at 98 Deutsches Drug-Eluting Stent Register sites. With similar baseline clinical and descriptive morphology of coronary artery disease between both drug-eluting stent groups, no differences were present at 1 year of follow-up in the rates of overall mortality (3.8% vs 4.1%), target vessel revascularization (10.4% vs 10.4%), overall stent thrombosis (3.6% vs 3.8%), and major adverse cardiac and cerebrovascular events (8.1% vs 8.0%). Compared with the bare metal stent group, patients treated with drug-eluting stents had significantly lower rates of myocardial infarction (3.2% vs 6.0%; p <0.01), stroke (1.2% vs 2.7%; p <0.05), and target vessel revascularization (10.4% vs 14.9%; p <0.01) without any difference in the stent thrombosis rate (3.7% vs 4.3%; p = 0.57) or mortality rate (4.0% vs 5.2%; p = 0.21). In conclusion, the data generated from the German Drug-Eluting Stent registry revealed no differences between patients receiving a paclitaxel-eluting stent and sirolimus-eluting stent in a "real-world" setting with regard to the clinical outcomes at 1 year. Crown Copyright
机译：前瞻性多中心德国药物洗脱支架（DES.DE）注册中心是一项观察性研究，旨在分析和评估在现实环境下，不同的药物洗脱支架（西罗莫司和紫杉醇洗脱支架）和裸金属支架的治疗原理。德国医疗体系的背景。记录所有入组患者的基线临床和血管造影特征以及一年的随访事件。另外，在最初放置支架后的3、6、9和12个月进行了健康经济学评估。主要目标是将死亡，心肌梗塞和中风的综合定义为主要的不良心脏和脑血管事件，以及靶血管的血运重建。从2005年10月到2006年10月，在98个德国药物洗脱支架登记处登记了6,384例患者（西罗莫司洗脱支架，n = 2,137;紫杉醇洗脱支架，n = 2,740;裸金属支架，n = 485）。两个药物洗脱支架组之间的基线临床和描述性冠状动脉疾病的基线相似，在随访1年时，总死亡率（3.8％vs 4.1％），靶血管血运重建（10.4％）无差异对比10.4％），整体支架血栓形成（3.6％对比3.8％）以及主要的不良心脏和脑血管事件（8.1％对比8.0％）。与裸金属支架组相比，接受药物洗脱支架治疗的患者的心肌梗塞发生率（3.2％vs 6.0％; p <0.01），中风（1.2％vs 2.7％; p <0.05）和目标血管的发生率明显更低血运重建（10.4％vs 14.9％; p <0.01），而支架内血栓形成率（3.7％vs 4.3％; p = 0.57）或死亡率（4.0％vs 5.2％; p = 0.21）没有任何差异。总之，从德国药物洗脱支架注册中心获得的数据显示，在“真实世界”环境中，接受紫杉醇洗脱支架和西罗莫司洗脱支架的患者在1年时的临床结局无差异。皇冠版权

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号